Recently, GoBroad Healthcare Group and Resolian, a global leader in bioanalytical and analytical science contract research services (CRO), officially signed a strategic cooperation agreement. By leveraging their respective core strengths and integrating resources, the two parties aim to jointly provide global biopharmaceutical clients with broader, more seamlessly connected, and fully integrated service solutions.

According to the agreement, the collaboration will follow a principle of steady advancement and deepening synergy, progressing in phases. The first phase of cooperation has recently been initiated, with a strong focus on seamless integration between market access and service delivery, enabling efficient end-to-end solutions from clinical research to bioanalysis.

Under this phase, GoBroad Healthcare Group will leverage its integrated clinical research capabilities to undertake and execute clinical services, while Resolian will provide high-quality bioanalytical testing through its global laboratory network. Chongqing Dinali, Resolian's laboratory in China, will be responsible for bioanalytical activities within the collaboration. Its consistently strong quality track record, validated through both domestic and international regulatory inspections, provides a solid and reliable operational foundation for this partnership.

This strategic alliance marks a significant milestone for both organizations in expanding service scope and strengthening regional collaboration. By combining GoBroad Healthcare Group’s clinical insight and execution capabilities with Resolian's global laboratory infrastructure and analytical expertise, the partnership is expected to enhance both resource efficiency and operational effectiveness, enabling clients to advance multi-regional development programs more smoothly.

Looking ahead, building on the success of the initial phase, both parties plan to explore deeper collaboration models, including potential joint development of new facilities, to further strengthen the partnership and jointly support the efficient development and successful commercialization of innovative medicines worldwide.